Mizoribine Versus Mycophenolatemofetil in Combination Therapy with Tacrolimus for De Novo Kidney Transplantation: Efficacy and Safety Evaluation

Trial Profile

Mizoribine Versus Mycophenolatemofetil in Combination Therapy with Tacrolimus for De Novo Kidney Transplantation: Efficacy and Safety Evaluation

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2013

At a glance

  • Drugs Mizoribine (Primary) ; Basiliximab; Methylprednisolone; Mycophenolate mofetil; Prednisolone; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jul 2012 New trial record
    • 01 Jan 2011 Primary endpoint 'Biopsy-proven-acute-transplant-rejection' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top